Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors?
Daniel W Lin
Correspondence Department of Urology, Box 356510, 1959 NE Pacific Street, University of Washington, Seattle, WA 98195, USA
Email dlin@u.washington.edu
This article has no abstract so we have provided the first paragraph of the full text.
While cisplatin-based chemotherapy for patients with advanced GCTs has yielded remarkable advancements in overall survival, a substantial proportion of men who initially present with metastatic disease will have persistent residual masses after chemotherapy. Models have been developed to predict the histology of these masses, and thus obviate postchemotherapy surgery in low-risk patients;1, 2 however, controversy remains over whether these models predict histology with acceptable accuracy. This study by Shayegan et al. adds information on the effectiveness of chemotherapy and the importance of surgery.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.